Mihaela Rebernik

Mihaela Rebernik


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Molecules
Verified
Journal Article
Open access
PDF file
JKJakob Kljun
Jakob Kljun
MRMihaela Rebernik
Mihaela Rebernik
LBLucia Mariana Balsa
Lucia Mariana Balsa
JKJerneja Kladnik
Jerneja Kladnik
URUroš Rapuš
Uroš Rapuš
ITIztok Turel
Iztok Turel
Organoruthenium pyrithione (1-hydroxypyridine-2-thione) complexes have been shown in our recent studies to be a promising family of compounds for development of new anticancer drugs. The complex [(η6-p-cymene)Ru(pyrithionato)(pta)]PF6 contains phosphine ligand pta (1,3,5-triaza-7-phosphaadamantane) as a functionality that improves the stability of the complex and its aqueous solubility. Here, we report our efforts to find pta alternatives and discover new structural elements to improve the biological properties of ruthenium anticancer drugs. The pta ligand was replaced by a selection of phosphine, phosphite, and arsine ligands to identify new functionalities, leading to improvement in inhibitory potency towards enzyme glutathione S-transferase. In addition, cytotoxicity in breast, bone, and colon cancers was investigated.